Impact Biomedical Secures Regulatory Approval to Advance Zoar Merger
New York, Tuesday, 3 November 2026.
Impact Biomedical cleared a major regulatory hurdle toward merging with Zoar Limited, positioning the combined entity to reach global markets spanning 35 countries ahead of a November 13, 2026 shareholder vote.
SEC Approval Paves Way for Landmark Biomedical Merger
Impact Biomedical Inc. (IBO) marked a significant regulatory milestone on October 23, 2026, when the U.S. Securities and Exchange Commission (SEC) declared effective the Form F-4 registration statement for its planned business combination with Zoar Limited [1][2]. The declaration represents a critical step in the proposed merger process, enabling Impact Biomedical to proceed with a definitive proxy statement and prospectus mailing to stockholders. The SEC’s action follows the company’s strategic transformation, including a 1-for-12.62 reverse stock split executed on September 23, 2026, which reduced shares outstanding from approximately 107.8 million to roughly 8.54 million [2].
Shareholder Vote Set for November 13, 2026
The next decisive phase of the merger process will occur on November 13, 2026, when Impact Biomedical stockholders convene for a special meeting at 10:00 a.m. Eastern Standard Time to vote on the proposed business combination [1]. The transaction, if approved, will result in the combined entity operating under the name Zoar Limited and listing its shares on the NYSE American exchange under the ticker symbol ‘ZOAR’, subject to final regulatory approvals [1][2]. Impact Biomedical CEO Frank D. Heuszel emphasized the significance of this milestone, stating that the SEC’s declaration of effectiveness ‘marks an important milestone as we advance toward completing our business combination with Zoar’ [1].
Strategic Vision for a Global Pharmaceutical Entity
Upon completion, the merged company will position itself as a global pharmaceutical powerhouse focused on the development and supply of active pharmaceutical ingredients (APIs) and intermediates, with Zoar Limited having already shipped over 85 pharmaceutical products to customers in 35 countries [1][2]. The merger represents a strategic shift for Impact Biomedical, transitioning from an early-stage intellectual property model to a manufacturing and clinical development enterprise with near-term emphasis on emerging markets [2]. This repositioning aligns with the company’s portfolio diversification, which includes the Linebacker polyphenol platform, Laetose sugar substitute, and antiviral blends such as Equivir/Equivir G [2][GPT].
Market Dynamics and Future Outlook
The pending merger remains subject to several closing conditions, including stockholder approval, NYSE American listing approval for Zoar’s ordinary shares, and satisfaction of other regulatory requirements [1][2]. Meanwhile, market indicators suggest a cautiously optimistic outlook for biotechnology stocks, which have experienced average weekly price growth of -1%, monthly growth of -13%, and quarterly growth of -20%, though some individual companies have bucked these trends [2][GPT]. For instance, Tickeron’s A.I.dvisor noted that Impact Biomedical’s Momentum Indicator moved above the 0 level on October 28, 2026, a signal historically preceding upward stock movements in 33 out of 41 similar instances, representing an 80% probability of a positive price trend [2].